1 ld be treated as a form of uterine papillary serous cancer.

2  management of early stage uterine papillary serous cancer.

3 parent for women >50 and women with invasive serous cancers.

4 were particularly common (23%) in high-grade serous cancers.

5 n the literature regarding uterine papillary serous cancer are that a potential precursor lesion, ser

6                                   High-grade serous cancers are characterized by few driver point mut

7                               In a number of serous cancer cell lines with a dysfunctional p53 pathwa

8 erscores STIC as a possible target for early serous cancer detection and prevention.

9                                   High-grade serous cancer (HGSC), the most common subtype of ovarian

10                            Uterine papillary serous cancer is an extremely aggressive cancer, the opt

11 platinum-sensitive recurrent EOC, peritoneal serous cancer, or fallopian tube cancer.

12 umors, increasing trends in risk of invasive serous cancer (p = 0.018), and particularly endometrioid

13 4.1% of patients overall, including 16.6% of serous cancer patients (high-gradeserous, 17.1%); [corre

14 ic women with BRCA mutations and linked to a serous cancer precursor in the fimbria.

15 ctomized mice continue to develop high-grade serous cancers, removal of the fallopian tube at an earl

16                    Stage I uterine papillary serous cancer requires aggressive treatment, including s

17                   The greatest proportion of serous cancer risk in BRCA mutation-positive women shoul

18    Large-scale genomic studies of high-grade serous cancer, the most common histotype, have identifie

19 emonstrate challenges for risk prediction of serous cancers, the most fatal subtype.

20    Besides the clinical resemblance to human serous cancers, these fallopian tube cancers highly expr

21  of endometrial carcinoma, uterine papillary serous cancer (UPSC).